About sihuan pharmaceutical holdings group ltd. - SHPHF
Sihuan Pharmaceutical Holdings Group Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. The Medical Aesthetic Products refers to the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care and others to provide non- or minimally invasive medical aesthetics comprehensive solutions. The company was founded by Feng Sheng Che and Wei Cheng Guo in 2001 and is headquartered in Beijing, China.
SHPHF At a Glance
Sihuan Pharmaceutical Holdings Group Ltd.
22nd floor, Building 4
Beijing, Beijing 100025
| Phone | 86-10-52278700 | Revenue | 364.20M | |
| Industry | Pharmaceuticals: Other | Net Income | 25.00M | |
| Sector | Health Technology | 2025 Sales Growth | 37.87% | |
| Fiscal Year-end | 12 / 2026 | Employees | 2,843 | |
| View SEC Filings |
SHPHF Valuation
| P/E Current | 44.444 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 58.528 |
| Price to Sales Ratio | 3.96 |
| Price to Book Ratio | 1.707 |
| Price to Cash Flow Ratio | 704.51 |
| Enterprise Value to EBITDA | 13.64 |
| Enterprise Value to Sales | 3.161 |
| Total Debt to Enterprise Value | 0.125 |
SHPHF Efficiency
| Revenue/Employee | 128,102.903 |
| Income Per Employee | 8,792.784 |
| Receivables Turnover | 1.474 |
| Total Asset Turnover | 0.234 |
SHPHF Liquidity
| Current Ratio | 1.803 |
| Quick Ratio | 1.578 |
| Cash Ratio | 1.11 |
SHPHF Profitability
| Gross Margin | 66.865 |
| Operating Margin | 14.991 |
| Pretax Margin | 15.491 |
| Net Margin | 6.864 |
| Return on Assets | 1.609 |
| Return on Equity | 3.481 |
| Return on Total Capital | 2.547 |
| Return on Invested Capital | 3.023 |
SHPHF Capital Structure
| Total Debt to Total Equity | 17.258 |
| Total Debt to Total Capital | 14.718 |
| Total Debt to Total Assets | 8.678 |
| Long-Term Debt to Equity | 13.02 |
| Long-Term Debt to Total Capital | 11.104 |